Royalty Pharma plc (RPRX) stock
RPRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 8/3049% above fair value
$68.53−0.78 (-1.13%)
Close on Nov 16, 2026Market cap $39.40BP/E 38.9Yield –
Royalty Pharma total debt
Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.
Royalty Pharma's total debt was $8.96B at Jun 30, 2026. For fiscal 2025 it was $8.95B, up 17.6% from the year before. The highest annual figure on record is $8.95B in fiscal 2025.
Annual total debt
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $8.95B | +17.6% |
| FY2024 | Dec 31, 2024 | $7.61B | +24.1% |
| FY2023 | Dec 31, 2023 | $6.14B | -13.8% |
| FY2022 | Dec 31, 2022 | $7.12B | +0.3% |
| FY2021 | Dec 31, 2021 | $7.10B | +22.0% |
| FY2020 | Dec 31, 2020 | $5.82B | -6.8% |
| FY2019 | Dec 31, 2019 | $6.24B | – |
Quarterly total debt
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $8.96B | +12.0% |
| Q1 FY2026 | Mar 31, 2026 | $8.96B | +17.6% |
| Q4 FY2025 | Dec 31, 2025 | $8.95B | +17.6% |
| Q3 FY2025 | Sep 30, 2025 | $8.95B | +17.6% |
| Q2 FY2025 | Jun 30, 2025 | $8.00B | +5.3% |
| Q1 FY2025 | Mar 31, 2025 | $7.62B | +24.1% |
| Q4 FY2024 | Dec 31, 2024 | $7.61B | +24.1% |
| Q3 FY2024 | Sep 30, 2024 | $7.61B | +24.1% |
| Q2 FY2024 | Jun 30, 2024 | $7.60B | +6.7% |
| Q1 FY2024 | Mar 31, 2024 | $6.14B | -13.8% |
| Q4 FY2023 | Dec 31, 2023 | $6.14B | -13.8% |
| Q3 FY2023 | Sep 30, 2023 | $6.13B | -13.8% |
| Q2 FY2023 | Jun 30, 2023 | $7.13B | +0.3% |
| Q1 FY2023 | Mar 31, 2023 | $7.12B | +0.3% |
| Q4 FY2022 | Dec 31, 2022 | $7.12B | +0.3% |
| Q3 FY2022 | Sep 30, 2022 | $7.11B | +0.3% |
| Q2 FY2022 | Jun 30, 2022 | $7.11B | +22.0% |
| Q1 FY2022 | Mar 31, 2022 | $7.10B | +22.0% |
| Q4 FY2021 | Dec 31, 2021 | $7.10B | +22.0% |
| Q3 FY2021 | Sep 30, 2021 | $7.09B | +22.0% |
| Q2 FY2021 | Jun 30, 2021 | $5.83B | -1.5% |
| Q1 FY2021 | Mar 31, 2021 | $5.82B | -6.7% |
| Q4 FY2020 | Dec 31, 2020 | $5.82B | – |
| Q3 FY2020 | Sep 30, 2020 | $5.81B | – |
| Q2 FY2020 | Jun 30, 2020 | $5.91B | – |
| Q4 FY2019 | Dec 31, 2019 | $6.24B | – |
See a number that looks wrong?